This is the event we were looking for and although this event did not have a large effect on the share price, we sold our shares this morning. Stimuvax looks like a promising drug and we will consider buying Biomira shares again in the future, but for now we don’t see any short term catalysts for Biomira so we will watch from the sidelines.
The next important event for Biomira will be either a new SEC filing or the next quarterly earnings announcement. One of these events will give investors the chance to find out the amount of the milestone payment by examining Biomira’s financial statements. This milestone payment amount is important because it could also shed some light on the royalty payment percentages Biomira would receive if Stimuvax is approved.